Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Signorelli, Mirko
• dc.contributor.author Ayoglu, Burcu
• dc.contributor.author Johansson, Camilla
• dc.contributor.author Lochmüller, Hanns
• dc.contributor.author Straub, Volker
• dc.contributor.author Muntoni, Francesco
• dc.contributor.author Niks, Erik
• dc.contributor.author Tsonaka, Roula
• dc.contributor.author Persson, Anja
• dc.contributor.author Aartsma-Rus, Annemieke
• dc.contributor.author Nilsson, Peter
• dc.contributor.author Al-Khalili Szigyarto, Cristina
• dc.contributor.author Spitali, Pietro
• dc.date.accessioned 2020-03-27T07:24:05Z
• dc.date.available 2020-03-27T07:24:05Z
• dc.date.issued 2020
• dc.description.abstract BACKGROUND: Duchenne muscular dystrophy (DMD) is a fatal disease for which no cure is available. Clinical trials have shown to be largely underpowered due to inter-individual variability and noisy outcome measures. The availability of biomarkers able to anticipate clinical benefit is highly needed to improve clinical trial design and facilitate drug development. METHODS: In this study, we aimed to appraise the value of protein biomarkers to predict prognosis and monitor disease progression or treatment outcome in patients affected by DMD. We collected clinical data and 303 blood samples from 157 DMD patients in three clinical centres; 78 patients contributed multiple blood samples over time, with a median follow-up time of 2 years. We employed linear mixed models to identify biomarkers that are associated with disease progression, wheelchair dependency, and treatment with corticosteroids and performed survival analysis to find biomarkers whose levels are associated with time to loss of ambulation. RESULTS: Our analysis led to the identification of 21 proteins whose levels significantly decrease with age and nine proteins whose levels significantly increase. Seven of these proteins are also differentially expressed in non-ambulant patients, and three proteins are differentially expressed in patients treated with glucocorticosteroids. Treatment with corticosteroids was found to partly counteract the effect of disease progression on two biomarkers, namely, malate dehydrogenase 2 (MDH2, P = 0.0003) and ankyrin repeat domain 2 (P = 0.0005); however, patients treated with corticosteroids experienced a further reduction on collagen 1 serum levels (P = 0.0003), especially following administration of deflazacort. A time to event analysis allowed to further support the use of MDH2 as a prognostic biomarker as it was associated with an increased risk of wheelchair dependence (P = 0.0003). The obtained data support the prospective evaluation of the identified biomarkers in natural history and clinical trials as exploratory biomarkers. CONCLUSIONS: We identified a number of serum biomarkers associated with disease progression, loss of ambulation, and treatment with corticosteroids. The identified biomarkers are promising candidate prognostic and surrogate biomarkers, which may support drug developers if confirmed in prospective studies. The serum levels of MDH2 are of particular interest, as they correlate with disease stage and response to treatment with corticosteroids, and are also associated with the risk of wheelchair dependency and pulmonary function.
• dc.description.sponsorship We acknowledge the Association Française Contre les Myopathies (grant no. 17724) and the Stichting Duchenne Parent Project for funding this work. We thank all members of the Affinity Proteomics group at SciLifeLab for technical assistance, as well as Prof. Mathias Uhlén and the entire staff of the Human Protein Atlas for their efforts. H.L. received funding by the Medical Research Council (MRC) Centre for Neuromuscular Diseases UK (reference G1002274 and grant ID 98482) and by the European Commission through the projects Neuromics (no. 305121) and RD‐Connect (no. 305444). The authors thank the MRC Centre for Neuromuscular Diseases for its support through the Neuromuscular Disease BioBank and the Muscular Dystrophy UK for its support to the Neuromuscular Centre at UCL. F.M. is supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre; the views expressed in this paper are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.
• dc.format.mimetype application/pdf
• dc.identifier.citation Signorelli M, Ayoglu B, Johansson C, Lochmüller H, Straub V, Muntoni F, Niks E, Tsonaka R, Persson A, Aartsma-Rus A, Nilsson P, Al-Khalili Szigyarto C, Spitali P. Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle. 2020; 11(2):505-17. DOI: 10.1002/jcsm.12517
• dc.identifier.doi http://dx.doi.org/10.1002/jcsm.12517
• dc.identifier.issn 2190-5991
• dc.identifier.uri http://hdl.handle.net/10230/44061
• dc.language.iso eng
• dc.publisher Wiley-VCH Verlag
• dc.relation.ispartof J Cachexia Sarcopenia Muscle. 2020; 11(2):505-17
• dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/305121
• dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/305444
• dc.rights © 2019 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Duchenne muscular dystrophy
• dc.subject.keyword Prognostic biomarker
• dc.subject.keyword Protein biomarkers
• dc.subject.keyword Rare diseases
• dc.subject.keyword Serum biomarkers
• dc.title Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion